about
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Unrelated donor hematopoietic transplantation.
@ast
Unrelated donor hematopoietic transplantation.
@en
Unrelated donor hematopoietic transplantation.
@nl
type
label
Unrelated donor hematopoietic transplantation.
@ast
Unrelated donor hematopoietic transplantation.
@en
Unrelated donor hematopoietic transplantation.
@nl
prefLabel
Unrelated donor hematopoietic transplantation.
@ast
Unrelated donor hematopoietic transplantation.
@en
Unrelated donor hematopoietic transplantation.
@nl
P2860
P1476
Unrelated donor hematopoietic transplantation.
@en
P2093
P2860
P304
P356
10.1046/J.1468-0734.2001.00035.X
P577
2001-06-01T00:00:00Z